Anixa Biosciences Secures Korean Patent for Breast Cancer Vaccine Technology
Event summary
- Anixa Biosciences received a Notice of Allowance from the Korean Ministry of Intellectual Property (MOIP) for a patent covering its breast cancer vaccine technology.
- The patent, titled 'Vaccine Adjuvants and Formulations,' was exclusively licensed from Cleveland Clinic and provides composition of matter protection in South Korea.
- Anixa's breast cancer vaccine generated immune responses in 74% of participants in a recently completed Phase 1 clinical trial conducted at Cleveland Clinic.
- The patent expands Anixa's global intellectual property portfolio, complementing patents issued in the United States and other key jurisdictions.
The big picture
Anixa Biosciences' patent approval in South Korea strengthens its position in the cancer immunotherapy field, particularly in preventive approaches. The growing international patent estate supports Anixa's strategy to pursue global opportunities and partner with larger pharmaceutical companies. This move aligns with broader industry trends towards preventive cancer treatments and the increasing incidence of breast cancer in younger populations in certain regions.
What we're watching
- Global Commercialization
- Whether Anixa can leverage this patent to secure partnerships with larger pharmaceutical companies for worldwide commercialization.
- Clinical Development
- The pace at which Anixa advances its breast cancer vaccine through further clinical trials in the U.S. and internationally.
- Market Opportunity
- How Anixa's technology could transform cancer prevention, particularly in markets with high breast cancer incidence rates like South Korea.
Related topics